How to manage regorafenib for a pt on 160-mg dose w/ HFS and some erythema, skin peeling but no pain (Gr 1)

A 67-year-old patient with extensive prior treatment for metastatic colorectal cancer (mCRC) is started on regorafenib 160 mg orally daily for 21 days every 28 days. About a week later, the patient develops Grade 2 hand-foot syndrome. What would you do at this time?

Same patient as above, but the patient develops Grade 1 hand-foot syndrome. What would you do at this time?

How to manage regorafenib for a pt on 160-mg dose w/ HFS and painful erythema, swelling (Gr 2)?

How to manage regorafenib for a pt on 160-mg dose w/ HFS and some erythema, skin peeling but no pain (Gr 1)?

A 67-year-old patient with extensive prior treatment for metastatic colorectal cancer (mCRC) is started on regorafenib 160 mg orally daily for 21 days every 28 days. About a week later, the patient develops Grade 2 hand-foot syndrome. What would you do at this time?

How to manage regorafenib for a pt on 160-mg dose w/ HFS and painful erythema, swelling (Gr 2)?

How to manage regorafenib for a pt on 160-mg dose w/ HFS and some erythema, skin peeling but no pain (Gr 1)?

A 67-year-old patient with extensive prior treatment for metastatic colorectal cancer (mCRC) is started on regorafenib 160 mg orally daily for 21 days every 28 days. About a week later, the patient develops Grade 2 hand-foot syndrome. What would you do at this time?

Usual starting dose of regorafenib? For a 75 yo pt?

In general, what is the usual starting dose of regorafenib that you use?

What is the starting dose that you use for a 75-year-old patient?

Usual starting dose of regorafenib? For a 75 yo pt?

In general, what is the usual starting dose of regorafenib that you use?

What is the starting dose that you use for a 75-year-old patient?

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, hematology-oncology fellows, oncology nurses, radiation oncologists, colorectal-general surgeons and other healthcare practitioners involved in the management of colorectal cancer.

OVERVIEW OF ACTIVITY

OVERVIEW OF ACTIVITY

Tx 45 yo w/ 0.8-cm node-neg, ER-neg/HER2+ early BC? Tx 70 yo w/ 1 pos node, ER-neg/HER2+ early BC?

Which systemic treatment do you generally use for a 45-year-old patient with node-negative, ER-negative, HER2-positive early breast cancer with a 0.8-cm tumor?

Which systemic treatment do you generally use for a 70-year-old woman with ER-negative, HER2-positive early breast cancer and 1 positive node?

60 yo, 2.1-cm node-neg IDC, ER-neg/HER2+, adj AC TH: Tx if lumpectomy bed recurrence 2 y later and NED?

How often would you use pertuzumab combined w/ trastuzumab/chemo in the neoadjuvant setting?

With approval of pertuzumab in the neoadjuvant setting, how often do you think you would use it in combination with trastuzumab/chemotherapy when using neoadjuvant treatment for HER2-positive disease?

Neoadj Tx pt w/ ER-neg/HER2+ T3 LABC wanting breast conservation?

Which neoadjuvant treatment do you generally use for a patient with locally advanced (T3 lesion), ER-negative, HER2-positive breast cancer who desires breast conservation?

Tx 45 yo w/ 0.8-cm node-neg, ER-neg/HER2+ early BC? Tx 70 yo w/ 1 pos node, ER-neg/HER2+ early BC?

Which systemic treatment do you generally use for a 45-year-old patient with node-negative, ER-negative, HER2-positive early breast cancer with a 0.8-cm tumor?

Which systemic treatment do you generally use for a 70-year-old woman with ER-negative, HER2-positive early breast cancer and 1 positive node?

60 yo, 2.1-cm node-neg IDC, ER-neg/HER2+, adj AC TH: Tx if lumpectomy bed recurrence 2 y later and NED?

How often would you use pertuzumab combined w/ trastuzumab/chemo in the neoadjuvant setting?

With approval of pertuzumab in the neoadjuvant setting, how often do you think you would use it in combination with trastuzumab/chemotherapy when using neoadjuvant treatment for HER2-positive disease?